Navigation Links
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
Date:2/20/2008

PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz (http://www.anapolschwartz.com/) attorney James Ronca (http://www.anapolschwartz.com/attorneys/jim_ronca.shtml), a New England Journal of Medicine study (http://content.nejm.org/cgi/content/short/358/8/771?query=TOC) (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.

Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit (http://www.anapolschwartz.com/practices/trasylol/) and a recent wrongful death complaint (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.

"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.

Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery (http://www.anapolschwartz.com/practices/trasylol/thompson-complaint.pdf) to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa., as well as Cherry Hill, N.J. (http://www.anapolschwartz.com/contactus.shtml) The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Contact: Alexandra Kane-Weiss/Jennifer Wasilisin

215-793-4666

akaneweiss@startoplin.com

jwasilisin@startoplin.com


'/>"/>
SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
2. St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards
3. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
10. Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit
11. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... ... ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited a home ... any heat. Shortly after entering the home, Paul was able to identify the problem ... carbon monoxide into the home, at 2,000 parts per million in the flue. Anything ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. ... department stores, announced it has raised $176,000 to benefit the Breast Cancer Research ... Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... "Company") (NASDAQ: UNIS ; ASX: UNS), a developer and ... for the second quarter of fiscal 2016 (three months ended December ... Financial Results for the Second Quarter of Fiscal 2016 ... the second quarter of fiscal 2016 was $4.5 million, compared to ... customers for the second quarter of fiscal 2016 were $17.8 million, ...
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Hearing protection devices refer to the barriers that reduce ... ear. Hearing protection devices include earplugs, uniform attenuation earplug, ... users exposed to noise levels of over 80 dB ... inserted in the ear canal to protect the ear. ... sound perception with the help of acoustic filters. Earmuffs ...
Breaking Medicine Technology: